Plus Therapeutics (PSTV) Change in Accured Expenses (2010 - 2026)
Plus Therapeutics (PSTV) reported Change in Accured Expenses of $489000.0 for Q1 2026, up 120.22% year-over-year from $222047.3 in Q1 2025, and down 28.92% quarter-over-quarter from $688000.0 in Q4 2025.
Plus Therapeutics (PSTV) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Change in Accured Expenses data on file, last reported at $489000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $489000.0, up 120.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.7 million (down 216.59% YoY), and the FY2025 annual result was -$5.6 million, down 219.52% from the prior year.
- Change in Accured Expenses retreated to $489000.0 in Q1 2026 per PSTV's latest filing, from $688000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $4.5 million in Q4 2022 and troughed at -$3.6 million in Q1 2023.
- A 5-year average of $138000.0 and a median of $384000.0 in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses soared 1884.43% in 2022, then slumped 5523.26% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $4.5 million in 2022, then tumbled by 91.46% to $384000.0 in 2023, then surged by 779.17% to $3.4 million in 2024, then tumbled by 79.62% to $688000.0 in 2025, then dropped by 28.92% to $489000.0 in 2026.
- Business Quant data shows PSTV's Change in Accured Expenses at $489000.0 in Q1 2026, $688000.0 in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - | 489,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 489,000.00 |
| Mar 31, 2026 | 489,000.00 |
| Dec 31, 2025 | 688,000.00 |
| Dec 31, 2025 | 688,000.00 |
| Sep 30, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | -2.76 Mn |
| Jun 30, 2025 | -2.76 Mn |
| Mar 31, 2025 | -2.42 Mn |
| Mar 31, 2025 | -2.42 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Sep 30, 2024 | 966,000.00 |
| Sep 30, 2024 | 966,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Dec 31, 2023 | 384,000.00 |
| Dec 31, 2023 | 384,000.00 |